Freeline Therapeutics Holdings

Freeline Therapeutics Holdings Plc operates as holding company whose subsidiaries provide biotechnology services. It develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Freeline Therapeutics Holdings Plc engages in the business of developing and commercializing gene therapies. It also develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Chunilal Nathwani in 2015 and is headquartered in Stevenage, the United Kingdom.

Freeline Therapeutics Holdings plc (NASDAQ:FRLN ) Q4 2022 Earnings Conference Call April 4, 2023 8:00 AM ET Company Participants Naomi Aoki - Senior Vice President, Head of Investor Relations & Corporate Communications Michael Parini - Chief Executive Officer Pam Foulds - Chief Medical Officer Paul Schneider - Chief Financial Officer Henning Stennicke - Chief Scientific Officer Conference Call Participants David Nierengarten - Wedbush Joe Hashmall - H.C. Wainwright Dae Gon Ha - Stifel Yun Zhong - BTIG Operator Good day, everyone.

Freeline Therapeutics Holdings plc (FRLN) Q4 2022 Earnings Call Transcript

Prioritizing development of FLT201, a potential first- and best-in-class gene therapy for most common type of Gaucher disease

Freeline Reports Full Year 2022 Financial Results and Provides Corporate Update

LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, April 4, 2023 to report its full year 2022 financial results and provide a corporate update.

Freeline Therapeutics to Host Full Year 2022 Financial Results Call

LONDON, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the closing of the previously announced sale of its CMC-focused German subsidiary, Freeline Therapeutics GmbH, along with certain related intellectual property, to Ascend Gene and Cell Therapies Ltd., for $25 million, subject to purchase price adjustments.

Freeline Announces Closing of Sale of Its CMC-Focused German Subsidiary

LONDON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on January 31, 2023, the Company granted two newly hired employees non-statutory options to purchase an aggregate of 81,000 of the Company's ordinary shares.

Freeline Reports January 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Data show increased enzyme activity and reduction of harmful substrate, an established biomarker of efficacy in Fabry disease, in key tissues and organs

Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy

LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on December 30, 2022, the Company granted four newly hired employees non-statutory options to purchase an aggregate of 48,900 of the Company's ordinary shares.

Freeline Reports December 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that it received approval from the Nasdaq Stock Market LLC (“Nasdaq”) to transfer the listing of its American Depositary Shares (“ADSs”) representing ordinary shares of the Company from The Nasdaq Global Select Market to The Nasdaq Capital Market. The transfer will be effective at the opening of business on November 30, 2022. The Company will continue to trade under the symbol “FRLN.”

Freeline Receives Approval to Transfer to Nasdaq Capital Market

Entered into definitive agreement to sell CMC-focused German subsidiary and related IP for $25 million, while retaining rights to AAVS3 capsid and maintaining access to capabilities and technologies

Freeline Reports Third Quarter 2022 Financial Results and Corporate Update

LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that Chief Executive Officer Michael Parini will participate in a fireside chat at the Stifel Healthcare Conference being held in New York.

Freeline to Present at the Stifel Healthcare Conference

LONDON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on October 31, 2022, the Company granted three newly hired employees non-statutory options to purchase an aggregate of 75,500 of the Company's ordinary shares.

Freeline Reports October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on September 30, 2022, the Company granted five newly hired employees non-statutory options to purchase an aggregate of 416,850 of the Company's ordinary shares.

Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that the first patient has been dosed in the second dose cohort of the Phase 1/2 MARVEL-1 clinical trial of FLT190 in Fabry disease, a debilitating inherited disorder that leads to progressive organ damage and can result in early death as a result of a harmful build-up of fat in cells due to an enzyme deficiency.

Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease

Freeline Announces Inducement Grants Freeline Announces Inducement Grants

Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

After losing some value lately, a hammer chart pattern has been formed for Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) Could Find Support Soon, Here's Why You Should Buy the Stock Now

Absci Corp

Axcella Health Inc

DiCE Molecules Holding LLC

 Pliant Therapeutics

Let us look at some drug/biotech stocks, ABSI, AXLA, FRLN, DICE and PLRX, which are poised to beat on second-quarter earnings.

5 Biotech Stocks Likely to Outpace Q2 Earnings Estimates

Six patients dosed in B-LIEVE trial of FLT180a in hemophilia B in four months and initial and emerging cohort one data reported, followed by NEJM publication of B-AMAZE long-term data

Freeline Reports Second Quarter 2022 Financial Results and Business Highlights

LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on July 29, 2022, the Company granted its newly hired Chief People Officer Nicole Jones and four other newly hired employees non-statutory options to purchase an aggregate of 240,000 and 35,250 of the Company's ordinary shares, respectively.

Freeline Announces July 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) Could be Great Choice for a Bottom Fisher

Treatment with FLT180a led to durable expression of coagulation factor IX (FIX) and strong decreases in both bleeding rates and need for FIX replacement among patients Treatment with FLT180a led to durable expression of coagulation factor IX (FIX) and strong decreases in both bleeding rates and need for FIX replacement among patients

New England Journal of Medicine Publishes Positive Long-Term Data on Freeline's Gene Therapy Candidate FLT180a for People with Hemophilia B

Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Freeline Therapeutics Holdings PLC Sponsored ADR (FRLN) Upgraded to Buy: Here's What You Should Know

Freeline Therapeutics Holdings plc (NASDAQ: FRLN) announced the presentation of safety and initial efficacy data from the first cohort of the Phase 1/2 B-LIEVE trial for FLT180a for hemophilia B. As of the data cut-off of May 23, 2022, a one-time FLT180a dose of 7.7e11 vg/kg.

Freeline Posts Cases Of Lower FIX Expression, Higher Liver Enzymes From Hemophilia Candidate

FLT180a generated protective FIX levels with no bleeding or need for FIX replacement

Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

uniQure

Genespire appoint s Dr. Sabah Sallah as Chief Medical Officer

Genespire appoints Dr. Sabah Sallah as Chief Medical Officer

LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on June 30, 2022, the Company granted a newly hired employee non-statutory options to purchase 5,500 of the Company's ordinary shares.

News for Freeline Therapeutics Holdings Stock (FRLN)